Meeting
2019 ASCO Annual Meeting
GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.
Authors
Bart Neyns
Universitair Ziekenhuis Brussel, Brussels, Belgium
Bart Neyns , Laila Ben Salama , Gil Awada , Jennifer De Cremer , Julia Katharina Schwarze , Laura Seynaeve , Stephanie Du Four , Lydia Fischbuch , Anne-Marie Vanbinst , Hendrik Everaert , Alex Michotte , Anne Rogiers , Peter Theuns , Johnny Duerinck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03291314
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2034)
DOI
10.1200/JCO.2019.37.15_suppl.2034
Abstract #
2034
Poster Bd #
223
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma.
First Author: Johnny Duerinck
Poster
2014 ASCO Annual Meeting
Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma.
First Author: Bart Neyns
Poster
2013 ASCO Annual Meeting
A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET).
First Author: Kathryn Maree Field
Poster
2023 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee